MEMatthias Evert

Matthias Evert

*This is an algorithmically generated author record based on publicly available information.

Matthias Evert has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The CDK4/6 inhibitor Palbociclib and the mTOR inhibitor MLN0128 are effective for the treatment of experimental intrahepatic cholangiocarcinoma

    by X Chen, M Evert, F Dombrowski, S Ribback, X Liu, X Song, K Utpatel, D Calvisi

    Question: Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer lacking effective therapies and is associated with highly dismal prognosis. Palbociclib is a pan CDK4/6 inhibitor that has been shown to inhibit cell proliferation in many experimental cancer models. Our recent studies demonstrate that mTOR inhibitors, such as MLN0128, induce ICC cell apoptosis, but possess limited efficacy in inhibiting cell proliferation. As ICC cells are known to be highly proliferative, we hypothesized that Palbociclib might synergize with MLN0128 to induce ICC regression. Methods: Thus, we tested the therapeutic efficacy of Palbociclib, either alone or in combination, with MLN0128 in human ICC cell lines as well as in the AKT/YapS127A ICC mouse model. Results: We found that in vitro Palbociclib inhibits ICC cell growth via inhibiting cell cycle progression. The long-term cell growth, but not the short-term cell survival to Palbociclib is RB-dependent. Strikingly, concomitant administration of Palbociclib and MLN0128 revealed a strong, synergistic effect in inhibiting ICC cell growth. In the AKT/YapS127A ICC preclinical model, treatment of Palbociclib or MLN0128 alone all led to restrained tumor growth. Of note, combined treatment of Palbociclib with MLN0128 resulted in significant tumor regression in these mice. Conclusion: In conclusion, the combination therapy of CDK4/6 inhibitors with mTOR inhibitors might represent a novel, promising, and effective therapeutic approach against ICC.

  • Open Access

    The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models

    by Silvia Ribback, Verena Sailer, Enrico Böhning, Julia Günther, Jaqueline Merz, Frauke Steinmüller, Kirsten Utpatel, Antonio Cigliano, Kristin Peters, Maria G. Pilo, et al.

    Activation of the epidermal growth factor receptor (EGFR) signaling pathway promotes the development of hepatocellular adenoma (HCA) and carcinoma (HCC). The selective EGFR inhibitor Gefitinib was found to prevent hepatocarcinogenesis in rat cirrhotic livers. Thus, Gefitinib might reduce progression of pre-neoplastic liver lesions to HCC. In short- and long-term experiments, administration of N-Nitrosomorpholine (NNM) or intrahepatic transplantation of pancreatic islets in diabetic (PTx), thyroid follicles in thyroidectomized (TTx) and ovarian fragments in ovariectomized (OTx) rats was conducted for the induction of foci of altered hepatocytes (FAH). Gefitinib was administered for two weeks (20 mg/kg) or three and nine months (10 mg/kg). In NNM-treated rats, Gefitinib administration decreased the amount of FAH when compared to controls. The amount of HCA and HCC was decreased, but development was not prevented. Upon all transplantation models, proliferative activity of FAH was lower after administration of Gefitinib in short-term experiments. Nevertheless, the burden of HCA and HCC was not changed in later stages. Thus, EGFR inhibition by Gefitinib diminishes chemical and hormonal also induced hepatocarcinogenesis in the initiation stage in the non-cirrhotic liver. However, progression to malignant hepatocellular tumors was not prevented, indicating only a limited relevance of the EGFR signaling cascade in later stages of hepatocarcinogenesis.


  • Polymorphism of the IL-8 gene and the risk of ovarian cancer

    by D. Koensgen, D. Bruennert, S. Ungureanu, D. Sofroni, E.I. Braicu, J. Sehouli, A. Sümnig, S. Delogu, M. Zygmunt, P. Goyal, et al.


  • 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras protooncogenes in mice

    by Df Calvisi, A Cigliano, C Wang, Mg Pilo, M Sini, F Dombrowski, X Chen, M Evert

    Concomitant expression of activated forms of AKT and Ras in the mouse liver (AKT/Ras) leads to rapid tumor development via strong activation of the mTORC1 pathway. mTORC1 functions via regulating p70S6K/RPS6 and 4EBP1/eIF4E cascades. How these cascades contribute to hepatocarcinogenesis remains unknown. Here, we show that inhibition of RPS6 pathway via Rapamycin effectively suppressed, whereas blockade of the 4EBP1/eIF4E cascade by 4EBP1A4, an unphosphorylatable form of 4EBP1, significantly delayed, AKT/Ras induced hepatocarcinogenesis. Combined treatment with Rapamycin and 4EBP1A4 completely inhibited AKT/Ras hepatocarcinogenesis. This strong anti-neoplastic effect was successfully recapitulated by ablating Raptor, the major subunit of mTORC1, in AKT/Ras-overexpressing livers. Furthermore, we demonstrate that overexpression of eIF4E, the protooncogene whose activity is specifically inhibited by 4EBP1, resulted in HCC development in cooperation with activated Ras. Mechanistically, we identified the ENTPD5/AK1/CMPK1 axis and the mitochondrial biogenesis pathway as targets of the 4EBP1/eIF4E cascade in AKT/Ras and Ras/eIF4E livers as well as in human HCC cell lines and tissues. Conclusions: Complete inhibition of mTORC1 is required to suppress liver cancer development induced by AKT and Ras protooncogenes in mice. The mTORC1 effectors, RPS6 and eIF4E, play distinct roles and are both necessary for AKT/Ras hepatocarcinogenesis. These new findings might open the way for innovative therapies against human hepatocellular carcinoma. Corresponding author: Evert, Matthias E-Mail: [email protected]

  • Open Access

    4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N‐Ras proto‐oncogenes in mice

    by Chunmei Wang, Antonio Cigliano, Lijie Jiang, Xiaolei Li, Biao Fan, Maria G. Pilo, Yan Liu, Bing Gui, Marcella Sini, Jeffrey W. Smith, et al.

    Concomitant expression of activated forms of v‐akt murine thymoma viral oncogene homolog (AKT) and Ras in mouse liver (AKT/Ras) leads to rapid tumor development through strong activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway. mTORC1 functions by regulating p70S6K/ribosomal protein S6 (RPS6) and eukaryotic translation initiation factor 4E‐binding protein 1/ eukaryotic translation initiation factor 4E (4EBP1/eIF4E) cascades. How these cascades contribute to hepatocarcinogenesis remains unknown. Here, we show that inhibition of the RPS6 pathway by rapamycin effectively suppressed, whereas blockade of the 4EBP1/eIF4E cascade by 4EBP1A4, an unphosphorylatable form of 4EBP1, significantly delayed, AKT/Ras‐induced hepatocarcinogenesis. Combined treatment with rapamycin and 4EBP1A4 completely inhibited AKT/Ras hepatocarcinogenesis. This strong antineoplastic effect was successfully recapitulated by ablating regulatory associated protein of mTORC1, the major subunit of mTORC1, in AKT/Ras‐overexpressing livers. Furthermore, we demonstrate that overexpression of eIF4E, the proto‐oncogene whose activity is specifically inhibited by 4EBP1, resulted in hepatocellular carcinoma (HCC) development in cooperation with activated Ras. Mechanistically, we identified the ectonucleoside triphosphate diphosphohydrolase 5/ adenylate kinase 1/cytidine monophosphate kinase 1 axis and the mitochondrial biogenesis pathway as targets of the 4EBP1/eIF4E cascade in AKT/Ras and Ras/eIF4E livers as well as in human HCC cell lines and tissues. Conclusions: Complete inhibition of mTORC1 is required to suppress liver cancer development induced by AKT and Ras proto‐oncogenes in mice. The mTORC1 effectors, RPS6 and eIF4E, play distinct roles and are both necessary for AKT/Ras hepatocarcinogenesis. These new findings might open the way for innovative therapies against human HCC. (Hepatology 2015;61:200–213)


  • Kidney protein profiling of Wilms' tumor patients by analysis of formalin-fixed paraffin-embedded tissue samples

    by Elke Hammer, Florian D. Ernst, Andrea Thiele, Narasimha Kumar Karanam, Christina Kujath, Matthias Evert, Uwe Völker, Winfried Barthlen


  • Synergistische Effekte von Beta-Catenin und YAP führen zur Entstehung von Hepatoblastomen in Mäusen und beim Menschen

    by Df Calvisi, J Tao, S Ranganathan, A Cigliano, L Jiang, B Fan, S Armeanu-Ebinger, S Delogu, S Ribback, F Dombrowski, et al.

    Der Wnt/Beta-Catenin- und der Yes-associated protein (YAP)-Signalweg regulieren beide das Organwachstum in der Embryogenese. Ihre aberrante Aktivierung wird unabhängig voneinander in Lebertumoren beobachtet. Aktivierende Mutationen oder Deletionen im Beta-Catenin-Gen können sowohl zu Hepatozellulären Karzinomen (HCC) als auch Hepatoblastomen (HB) führen. Die pathogenetische Bedeutung von YAP, dem wesentlichen transkriptionellen Mediator des Hippo-Kinase-Signalwegs, ist hingegen weniger gut verstanden und über ein mögliches Zusammenspiel dieser beiden onkogenen Signalwege für die Lebertumorentstehung ist kaum etwas bekannt. In einem Kollektiv humaner HB fanden wir eine Ko-Expression von Beta-Catenin and YAP1 in 79% der Fälle, hingegen in keinem der Kontrolltumoren (HCC oder cholangiozelluläre Karzinome). Die Bedeutung einer Ko-Aktivität dieser Onkogene für die Lebertumorentstehung haben wir daraufhin in vivo untersucht: Die Ko-Injektion von aktiviertem Beta-Catenin (ΔN90-β-catenin) und aktiviertem YAP (YapS127A; mit intaktem TEAD-Bindungsvermögen) in Mäuse durch hydrodynamischen Gentransfer mit nachfolgender sleeping beauty Transposase-mediierter genomischer Integration der Genkonstrukte in reife Hepatozyten, führte zu einer raschen Entstehung von Lebertumoren, von denen einige histomorphologisch HB des Menschen ähnelten. Nach 11 Wochen ergab sich eine 100%-ige tumorbedingte Mortalität der Tiere. Immunhistochemisch und durch Immunoblotting zeigte sich neben der kombinierten Überexpression des injizierten Beta-Catenins und von YAP1 auch eine starke Aktivierung derer Zielstrukturen wie Axin-2, Cyclin-D1, CTGF, und Jag1. In vitro führte die Suppression von YAP1 zu einem starken Aktivitätsverlust des Beta-Catenin-Signals in HB-Zellen (TOPflash Reporter Aktivitäts-Assay). Zudem war die kombinierte Inhibition von Beta-Catenin and YAP1 deutlich effektiver wachstumshemmend für die Tumorzellen als ein Inhibitor alleine. Wir schlussfolgern daher, dass der Synergismus von YAP and Beta-Catenin für die Entstehung und den Progress von HB bei der Maus und beim Menschen von besonderer Bedeutung ist.

  • Active Ras signaling is involved in the transcriptional upregulation of the functional p53 inhibitor MDM4 in human and murine hepatocellular carcinoma

    by R Pellegrino, Df Calvisi, X Chen, M Evert, F Dombrowski, P Schirmacher, T Longerich

    MDM4 is a p53 binding protein that negatively regulates p53-dependent transcription. MDM4 was found overexpressed in a variety of human cancers and amplifications of the MDM4 gene locus were reported with high frequency in most of the tumors analyzed. We have previously demonstrated that MDM4 is upregulated in about 50% of human hepatocellular carcinomas (HCC), both at messenger RNA and protein level. Although we identified 1q32 gain as a mechanism leading to MDM4 overexpression in human HCCs, many liver tumors display a balanced MDM4 gene locus. Thus, additional mechanisms are responsible for MDM4 aberrant expression in the presence of an intact MDM4 locus. The transcriptional regulation of MDM4 remains largely elusive. Here, we show that activation of the Ras/ERK signaling pathway is involved in the transcriptional upregulation of MDM4 in human HCCs thereby supporting its protumorigenic function. Following treatment with the specific MEK inhibitor U0126 we observed a strong decrease of the MDM4 protein level in a time-dependent manner in HCC cell lines, which resulted in the re-activation of p53 target genes (e.g. PUMA, BAX and p21). Similar results were obtained following siRNA-mediated targeting of the transcription factor ELK1, a direct downstream effector of activated ERK proteins. Both MEK inhibition and ELK1 silencing triggered a remarkable decrease of MDM4 mRNA levels in HCC cell lines when compared to untreated cells. Functional re-activation of p53 function was indicated by decreased cell viability following ELK1 knockdown. Moreover, both preneoplastic and neoplastic liver lesions of AKT/Ras transgenic mice showed significantly higher MDM4 protein levels compared to both wild-type and AKT monotransgenic mice. Taken together, our data demonstrate a crucial role of the Ras/ERK axis in the transcriptional activation of MDM4 expression, thereby supporting the oncogenic MDM4 activity in HCC in vitro and in vivo.

  • Akt/Notch activation drives rapid cholangiocarcinoma development originating from mature hepatocytes in the mouse

    by M Evert, B Fan, Y Malato, S Ribback, F Dombrowski, H Willenbring, X Chen, Df Calvisi

    Introduction: Intrahepatic cholangiocarcinomas (ICCs) are primary liver tumors with a dismal prognosis. Activated AKT/mTOR pathway promotes both HCC and ICC development in the mouse liver. Notch signaling is known to play a critical role during bile duct development. Here we hypothesized that activated Notch signaling converted AKT-overexpressing preneoplastic hepatocytes into ICC in vivo. Methods: Activated Notch (NICD) alone or together with the activated form of AKT (myr-AKT) were stably transfected into the mouse liver via hydrodynamic injection. Dominant negative form of RBP-J (dnRBP-J) was co-injected with AKT to block canonical Notch pathway in the mice. Notch and AKT pathway status was determined in human ICC samples by Western blotting and immunohistochemical staining. Results: Overexpression of NICD alone induced cystic cholangiocellular tumors, including cystic ICCs, over long latency. Concomitant activation of Notch and AKT signaling synergized to promote rapid cholangiocarcinogenesis in mice. Intriguingly, we found that the ICC tumor cells originated from mature hepatocytes. Using a mouse model of hepatocyte fate tracing in combination with morphological and ultrastrutural evaluation by light and electron microscopy, we demonstrated that Notch and AKT coexpression transformed normal hepatocytes into ICCs. The hepatocyte-cholangiocyte conversion occurred at the earliest stages of the tumorigenic process, supporting that it is the critical step leading to the malignant initiation and subsequent progression. Mechanistic studies revealed the increase in both cell proliferation and glycolysis in AKT/NICD induced ICC lesions. Furthermore, blocking canonical Notch signaling with dnRBP-J in AKT-injected mice prevented ICC, but not HCC development in these mice, supporting that AKT-induced ICC development was dependent on Notch signaling. Finally, coordinated activation of AKT and Notch signaling was detected in a subset of human ICC samples. Conclusion: Our studies suggest that hepatocytes can be the cellular origin of ICC in mice and possibly also in humans. Activated AKT and Notch signaling pathways have critical roles during ICC development, and targeted therapy against these pathways may be useful in treating human ICC.

  • Complete inhibition of mTORC1 cascade is required to suppress hepatocarcinogenesis induced by AKT and Ras co-expression

    by Df Calvisi, C Wang, B Fan, L Jiang, A Cigliano, S Delogu, F Dombrowski, X Chen, M Evert

    Introduction: AKT and Ras pathways are frequently concurrently hyperactivated in HCC. Previously, we have shown that co-expression of constitutively active forms of AKT (Myr-AKT) and activated Ras (N-RasV12) rapidly induces liver tumors in mice. mTORC1 is the main downstream effector of AKT, acting by phosphorylation of RPS-6 and 4E-BP1, and thus regulating cell metabolism, protein translation and other cellular processes. However, in which manner mTORC1 and its key downstream effectors RPS-6 and 4E-BP1/eIF4E do contribute to hepatocarcinogenesis remains unknown. Methods: Plasmids encoding Myr-AKT, RasV12, 4EBP1A4 (dominant negative form of 4E-BP1), or 4EBP1WT (wild type) were delivered into the mouse liver by hydrodynamic injection. The mTORC1 inhibitor Rapamycin or vehicle were intraperitoneally administrated into the mice. Western blotting and immunohistochemistry were performed to analyze the expression levels of proteins in the tissues. Results: To determine whether the mTORC1 downstream effector RPS6 is required for hepatocarcinogenesis in AKT/Ras mice, we treated AKT/Ras mice with rapamycin (AKT/RAS/Rapa) or vehicle (AKT/RAS/Veh) daily for 7 weeks. All of the AKT/RAS/Veh mice developed large HCCs and were required to be euthanized. By contrast, none of the AKT/RAS/Rapa mice showed HCC, but microscopically small regressive tumor-like nodules and preneoplastic hepatocellular foci were still visible. In addition, withdrawal of rapamycin treatment was followed by a relapse in HCC development. Biochemical analysis demonstrated that Rapamycin inhibited the phosphorylation of RPS6, but had no effect on phosphorylated/inactivated levels of 4E-BP1. To define the role of 4EBP1/eIF4E in AKT/Ras-driven hepatocarcinogenesis, we overexpressed 4EBP1A4 or 4EBP1WT along with AKT and Ras into the mouse liver. Seven weeks after hydrodynamic injection, AKT/Ras/4EBP1WT mice developed large HCC which were equivalent to those developed in AKT/RAS/Veh mice. However, only few very small hepatocellular adenomas (HCA) developed in the livers of AKT/Ras/4EBP1A4 mice. These lesions, together with preneoplastic hepatocytes, occupied 40–60% of the liver parenchyma. 20 weeks post injection, the AKT/Ras/4EBP1A4 mice eventually developed large liver tumors, including HCC. These results indicated that inhibition of 4E-BP1/eIF4E axis efficiently delayed the AKT/RAS induced liver tumor, yet was unable to completely block the tumorigenesis process. Finally, we co-injected AKT/Ras mice with 4EBP1A4 and treated the mice with Rapamycin. We found that simultaneously blocking p-RPS6 and p-4EBP1 completely inhibited AKT/Ras induced hepatic carcinogenesis. Conclusion: Our experiments demonstrate the critical role of mTORC1 in mediating activated AKT and Ras induced liver tumor development in vivo. The two major downstream effectors of mTORC1, RPS6 and 4E-BP1/eIF4E, are both required for tumorigenesis. Yet they are likely to have distinct roles within the neoplastic process.